Targeted therapy prolongs life in patients with HER2-positive breast cancer
Submitted by MedicalReplies on Sunday, 27 December 2009No Comment
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to new research.
Read the rest here:
Targeted therapy prolongs life in patients with HER2-positive breast cancer
Leave your response!